摘要
Breast cancer(BC)is now the most common cancer and the fifth leading cause of cancer-associated mortality among women in China1.Germline pathogenic variants(PVs)of BC susceptibility genes,such as the well-known BRCA1/2 genes,increase the risk of BC and other cancers(ovarian and pancreatic cancer)^(2,3).Recent studies have demonstrated substantial benefits of poly(adenosine diphosphate ribose)polymerase inhibitors in the treatment of BC patients who carry BRCA1/2 PVs^(4).
基金
supported by grants from the National Natural Science Foundation of China(Grant Nos.82272932,81974422,and 92359201).
